26 Jul Xintela
Stijn Heessen, Ph.D., Chief Business Officer
Oct. 8 | 11:30am | FLW Ballroom G
Lund, Sweden
(Public: XINT)
Xintela is a clinical-stage biopharma company developing novel allogeneic mesenchymal stem cell (MSC) therapies based on its proprietary stem cell marker technology. Xintela’s best-in-class stem cell product XSTEM® is in Phase I/IIa clinical development in knee osteoarthritis (OA) (completed) and difficult-to-heal venous leg ulcers (VLU). The 18-month interim analysis demonstrated safety and significant sustained pain reduction and improvement of joint function as well as improvement of bone and cartilage structure in the OA study. The final study report includes up to 24-month follow-up data. The VLU study is also near completion. XSTEM® differentials:
– Consists of homogenous, integrin α10β1-selected MSCs with superior potency and consistency
– Clinical data demonstrate safety, efficacy and a disease-modifying mode-of-action
– Protected with granted product patents for all therapeutic uses
– Manufactured in Xintela’s in-house GMP facility
